The Menarini Group a privately held Italian pharmaceutical and diagnostics company today announced it has acquired Silicon Biosystems S.p.A. a provider of specialized molecular and cellular biology technologies capable of recovering and analyzing tumor cells from blood samples. Silicon Biosystems' DEPArray™ and Ampli1™ genomic analysis technologies are being used in clinical research to advance the development of cancer diagnostics and accelerate the age of precision medicine through personalized therapies. Financial terms of the acquisition were not disclosed.
"The acquisition of Silicon Biosystems represents a unique opportunity for the Menarini Group to add an innovative high-tech company to our existing pharmaceutical and biotechnology programs in oncology" said Lucia Aleotti Chairman of the Menarini Group. "We are excited by the high potential of Silicon Biosystems' technology and the possibility we will have to dramatically impact patients' lives."